TOPLINE:

In a multicentre real-world study, treatment with amivantamab was associated with diverse dermatologic adverse events in patients with non-small cell lung cancer (NSCLC), with 65.9% developing multiple toxicities and 26.7% experiencing adverse events of grade 3 or higher.

METHODOLOGY:

• Researchers conducted a retrospective, multicentre observational study including 135 patients with NSCLC (mean age, 62.3 years; 60.7% women) at expert dermatology centres participating in the European Academy of Dermatology and Venereology Task Force.
• Patients in the study received at least one dose of amivantamab, either as monotherapy or in combination with lazertinib, chemotherapy, or osimertinib, and developed at least one dermatologic adverse event.
• Outcomes included the real-world spectrum, severity, and management of dermatologic adverse events associated with amivantamab.

TAKEAWAY:

• Researchers identified 16 distinct dermatologic adverse events, with acneiform rash (70.4%), paronychia (51.9%), and scalp ulcerative lesions (31.1%) being the most frequent manifestations. Ulcerative lesions involving the genital, perianal, or oral mucosa were observed in 11.1% of patients.
• Combination therapy with lazertinib was linked to a significantly higher number of dermatologic adverse events than amivantamab monotherapy or amivantamab combined with chemotherapy (P < .001). An increased occurrence of paronychia was observed in the lazertinib group (P = .025), and an increased occurrence of genital and perianal ulcerations was reported in patients receiving chemotherapy (P = .010).
• Most of the acneiform rash and 75.7% of patients with paronychial lesions and these rashes were treated with oral tetracyclines.
• Scalp ulcerative lesions were treated with oral tetracyclines, topical or systemic corticosteroids, topical antibiotics, or a combination of these therapies.

IN PRACTICE:

"Amivantamab is associated with a broad and sometimes severe spectrum of dAEs [dermatologic adverse events] in real-world practice. Awareness of characteristic ulcerative scalp and mucocutaneous presentations, together with timely dermatologic assessment, is essential to support continuation of oncologic therapy," the authors wrote.

SOURCE:

This study was led by Vasiliki Nikolaou, 1st Department of Dermatology and Venereology, "Andreas Syngros" Hospital for Skin Diseases, National & Kapodistrian University of Athens Medical School, Athens, Greece. It was published online on February 11, 2026, in the Journal of the European Academy of Dermatology & Venereology.

LIMITATIONS:

The high frequency of scalp ulcerative lesions and severe dermatologic toxicities observed in the study might reflect referral bias inherent to specialised oncodermatology centres, potentially affecting the generalisability of the findings.

DISCLOSURES:

This study did not receive any funding. The authors reported having no relevant conflicts of interest.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.